Carcinosarcoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MMMT MCID: CRC021 MIFTS: 62	Carcinosarcoma (MMMT) Categories: Bone diseases, Cancer diseases, Rare diseases, Reproductive diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Carcinosarcoma

MalaCards integrated aliases for Carcinosarcoma:

Name: Carcinosarcoma ¹² ⁵⁴ ⁵⁶ ⁴⁵ ¹⁵

Malignant Mixed Mullerian Tumor ¹² ⁵⁴

Mixed Tumor, Mesodermal ⁴⁵ ¹⁷

Mixed Tumor, Mullerian ⁵⁴ ⁴⁵

Mmmt ¹² ⁵⁴

Malignant Mixed Mesodermal Tumor ¹²

Malignant Mixed Müllerian Tumor ⁷⁷

Mixed Mesodermal Tumor ¹²

Mesodermal Mixed Tumor ¹²

Mullerian Mixed Tumor ¹²

Mixed Müllerian Tumor ⁷⁷

Mixed Mullerian Tumor ⁵⁴

Mixed Tumor Mullerian ⁵⁶

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Bone diseases Reproductive diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:4236

MeSH ⁴⁵ D002296 D018199 D018200

NCIt ⁵¹ C34448 C3730 C8975

SNOMED-CT ⁶⁹ 63264007 84427001

EFO ¹⁷ EFO_1001371

UMLS ⁷⁴ C0007140 C0206627 C1334603

Sources

Summaries for Carcinosarcoma

NIH Rare Diseases : ⁵⁴ A malignant mixed müllerian tumor (MMMT), also called a carcinosarcoma, is a type of cancer that contains two types of cancer cells - carcinoma and sarcoma cells. These tumors usually develop in tissues of the female genital tract and are associated with a poor outcome. The majority of these tumors arise in the uterus, though they can also occur in the ovaries, fallopian tubes, and cervix. Very rarely, MMMTs can develop in the female peritoneum (lining of the abdominal wall).

MalaCards based summary : Carcinosarcoma, also known as malignant mixed mullerian tumor, is related to cervical carcinosarcoma and uterine carcinosarcoma. An important gene associated with Carcinosarcoma is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Paclitaxel and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include uterus, ovary and breast, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : ¹² A mixed cell type cancer that has material basis in carcinomatous (epithelial tissue) and sarcomatous (connective tissue) components.

Wikipedia : ⁷⁷ A malignant mixed Müllerian tumor, also known as malignant mixed mesodermal tumor (MMMT) is a cancer... more...

Sources

Related Diseases for Carcinosarcoma

Diseases related to Carcinosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 498)

#	Related Disease	Score	Top Affiliating Genes
1	cervical carcinosarcoma	33.5	MME PGR TP53
2	uterine carcinosarcoma	32.0	CTNNB1 ERBB2 HRAS KIT MME PGR
3	adenosarcoma	31.6	DES KIT MME PGR TP53
4	adenomyoma	31.2	CTNNB1 KRT7 MME MUC1
5	papillary serous adenocarcinoma	30.3	KRT7 PGR TP53
6	rhabdomyosarcoma	30.3	ACTC1 DES TP53 VIM
7	papilloma	30.3	KRT7 PTEN TP53
8	breast metaplastic carcinoma	30.3	ERBB2 PGR
9	uterine sarcoma	30.2	DES KIT MME
10	liposarcoma	30.2	DES TP53 VIM
11	pleomorphic adenoma	30.1	ACTC1 ERBB2 MUC1 TP53 VIM
12	uterine corpus serous adenocarcinoma	30.1	ERBB2 PIK3CA TP53
13	pulmonary blastoma	30.1	DES KRAS TP53
14	thymoma	30.1	HRAS KIT TP53
15	spindle cell thymoma	30.1	DES MUC1
16	epithelial-myoepithelial carcinoma	29.9	HRAS KRT7 TP53
17	spiradenoma	29.9	ACTC1 KRT7 MUC1 TP53
18	pleomorphic liposarcoma	29.9	DES MUC1 VIM
19	fallopian tube carcinoma	29.9	ERBB2 PGR TP53
20	mucoepidermoid carcinoma	29.9	ERBB2 KRT7 MUC1
21	teratoma	29.9	ACTC1 KIT KRT7 TP53
22	in situ carcinoma	29.9	ERBB2 PGR TP53
23	tubular adenocarcinoma	29.8	ERBB2 MUC1 PGR
24	spindle cell carcinoma	29.8	ACTC1 DES KRT7 MUC1 PGR VIM
25	squamous cell carcinoma	29.8	CTNNB1 ERBB2 HRAS MUC1 PIK3CA PTEN
26	adenofibroma	29.8	ACTC1 MME MUC1 VIM
27	spindle cell sarcoma	29.7	ACTC1 DES KRT7 MUC1 VIM
28	fibrous histiocytoma	29.7	ACTC1 DES VIM
29	dermoid cyst	29.7	KIT KRT7 MUC1 PGR VIM
30	ovarian cancer 1	29.7	ERBB2 KRAS KRT7 PIK3CA TP53
31	merkel cell carcinoma	29.6	KIT KRT7 MUC1 TP53
32	gliosarcoma	29.6	ACTC1 PTEN TP53 VIM
33	leiomyosarcoma	29.6	ACTC1 DES KIT PGR TP53 VIM
34	angiosarcoma	29.5	KIT KRAS MUC1 VIM
35	malignant fibroxanthoma	29.5	ACTC1 DES MUC1 VIM
36	mucinous adenocarcinoma	29.5	KRAS KRT7 MUC1
37	serous cystadenocarcinoma	29.5	ERBB2 HRAS PGR PIK3CA TP53
38	small cell cancer of the lung	29.5	KIT KRT7 PIK3CA PTEN TP53
39	undifferentiated pleomorphic sarcoma	29.4	KIT KRAS PIK3CA
40	chordoma	29.4	DES KRT7 MUC1 PTEN VIM
41	sarcoma	29.4	CTNNB1 HRAS KIT KRAS PIK3CA TP53
42	ovary adenocarcinoma	29.3	ERBB2 HRAS KRAS KRT7 PIK3CA TP53
43	inflammatory myofibroblastic tumor	29.2	ACTC1 DES KIT TP53 VIM
44	papillary adenocarcinoma	29.2	ERBB2 KRT7 MUC1 PGR TP53 VIM
45	cystadenocarcinoma	29.1	ERBB2 HRAS KRT7 MUC1 PGR PIK3CA
46	wilms tumor 1	29.1	CTNNB1 ERBB2 KRT7 PGR TP53
47	cervical cancer	29.1	CTNNB1 ERBB2 HRAS PIK3CA PTEN TP53
48	adenosquamous carcinoma	29.0	KIT KRAS KRT7 MUC1 PIK3CA TP53
49	endometrial stromal sarcoma	28.9	ACTC1 DES KIT MME PGR TP53
50	adenocarcinoma	28.8	CTNNB1 ERBB2 HRAS KIT KRAS MUC1

Graphical network of the top 20 diseases related to Carcinosarcoma:

Sources

Symptoms & Phenotypes for Carcinosarcoma

GenomeRNAi Phenotypes related to Carcinosarcoma according to GeneCards Suite gene sharing:

²⁷ (show all 15)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00055-A-2	10.3	HRAS KRAS MUC1 PIK3CA
2	Decreased viability	GR00106-A-0	10.3	KRAS
3	Decreased viability	GR00221-A-1	10.3	HRAS KRAS PIK3CA
4	Decreased viability	GR00221-A-2	10.3	HRAS KRAS PIK3CA
5	Decreased viability	GR00221-A-3	10.3	HRAS
6	Decreased viability	GR00221-A-4	10.3	PIK3CA
7	Decreased viability	GR00301-A	10.3	KRAS
8	Decreased viability	GR00381-A-1	10.3	KRAS
9	Decreased viability	GR00402-S-2	10.3	HRAS KRAS MUC1 PIK3CA
10	Decreased viability in esophageal squamous lineage	GR00235-A	10	CTNNB1 DES ERBB2 HRAS KIT KRAS
11	Decreased cell migration	GR00055-A-1	9.88	CTNNB1 HRAS KRAS MUC1 PIK3CA VIM
12	Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance	GR00210-A	9.85	CTNNB1 ERBB2 HRAS MUC1 PTEN VIM
13	Increased cell death HMECs cells	GR00103-A-0	9.55	CTNNB1 PGR PIK3CA PTEN TP53
14	Increased cell migration	GR00055-A-3	9.26	CTNNB1 HRAS KRAS PIK3CA
15	Reduced mammosphere formation	GR00396-S	9.1	DES HRAS KRAS KRT7 PTEN VIM

MGI Mouse Phenotypes related to Carcinosarcoma:

⁴⁷ (show all 23)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.4	ACTC1 CTNNB1 DES ERBB2 HRAS KIT
2	cardiovascular system	MP:0005385	10.38	ACTC1 CTNNB1 DES ERBB2 HRAS KIT
3	cellular	MP:0005384	10.38	ACTC1 CTNNB1 DES ERBB2 KIT KRAS
4	behavior/neurological	MP:0005386	10.35	CTNNB1 DES ERBB2 HRAS KIT KRAS
5	mortality/aging	MP:0010768	10.29	ACTC1 CTNNB1 DES ERBB2 HRAS KIT
6	integument	MP:0010771	10.24	CTNNB1 ERBB2 HRAS KIT KRAS MME
7	muscle	MP:0005369	10.24	ACTC1 CTNNB1 DES ERBB2 KIT KRAS
8	embryo	MP:0005380	10.23	CTNNB1 ERBB2 KIT KRAS PGR PIK3CA
9	endocrine/exocrine gland	MP:0005379	10.22	CTNNB1 ERBB2 HRAS KIT KRAS PGR
10	immune system	MP:0005387	10.2	CTNNB1 KIT KRAS MME PGR PIK3CA
11	digestive/alimentary	MP:0005381	10.13	CTNNB1 ERBB2 HRAS KIT KRAS PTEN
12	neoplasm	MP:0002006	10.13	CTNNB1 ERBB2 HRAS KIT KRAS PGR
13	nervous system	MP:0003631	10.11	CTNNB1 ERBB2 HRAS KIT KRAS PIK3CA
14	craniofacial	MP:0005382	10.07	CTNNB1 ERBB2 HRAS KIT KRAS TP53
15	limbs/digits/tail	MP:0005371	10.07	CTNNB1 ERBB2 KIT KRAS PGR PTEN
16	normal	MP:0002873	10.06	ACTC1 CTNNB1 ERBB2 HRAS KIT KRAS
17	no phenotypic analysis	MP:0003012	9.98	CTNNB1 HRAS KIT KRAS PGR PIK3CA
18	reproductive system	MP:0005389	9.91	CTNNB1 ERBB2 KIT KRAS PGR PIK3CA
19	renal/urinary system	MP:0005367	9.87	CTNNB1 HRAS KIT KRAS KRT7 PTEN
20	pigmentation	MP:0001186	9.77	CTNNB1 KIT KRAS PTEN TP53
21	respiratory system	MP:0005388	9.76	CTNNB1 ERBB2 HRAS KIT KRAS PTEN
22	skeleton	MP:0005390	9.61	CTNNB1 ERBB2 HRAS KIT KRAS PGR
23	vision/eye	MP:0005391	9.17	CTNNB1 KIT KRAS PIK3CA PTEN TP53

Sources

Drugs & Therapeutics for Carcinosarcoma

Drugs for Carcinosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 114)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Paclitaxel

Approved, Vet_approved

Phase 3,Phase 2,Phase 1,Not Applicable

33069-62-4

36314

Carboplatin

Approved

Phase 3,Phase 2,Phase 1,Not Applicable

41575-94-4

38904 10339178 498142

Gemcitabine

Approved

Phase 2, Phase 3

95058-81-4

60750

Ifosfamide

Approved

Phase 3,Phase 2

3778-73-2

3690

Lenograstim

Approved, Investigational

Phase 3,Phase 1

135968-09-1

Mechlorethamine

Approved, Investigational

Phase 3,Phase 2

51-75-2

4033

Cisplatin

Approved

Phase 3,Phase 2,Phase 1

15663-27-1

441203 84093 2767

Mesna

Approved, Investigational

Phase 3,Phase 2

3375-50-6

598

Bevacizumab

Approved, Investigational

Phase 3,Phase 2,Phase 1

216974-75-3

Doxorubicin

Approved, Investigational

Phase 3,Phase 2,Phase 1

23214-92-8

31703

Niraparib

Approved, Investigational

Phase 2, Phase 3

1038915-60-4

24958200

Topotecan

Approved, Investigational

Phase 2, Phase 3

123948-87-8, 119413-54-6

60700

Cyproheptadine

Approved

Phase 3

129-03-3

2913

Histamine

Approved, Investigational

Phase 3

51-45-6

774

Doxil

Approved June 1999

Phase 3,Phase 2,Phase 1

31703

Antineoplastic Agents, Alkylating

Phase 3,Phase 2

Albumin-Bound Paclitaxel

Phase 3,Phase 2,Phase 1,Not Applicable

Alkylating Agents

Phase 3,Phase 2

Antimitotic Agents

Phase 3,Phase 2,Phase 1,Not Applicable

Antineoplastic Agents, Phytogenic

Phase 3,Phase 2,Phase 1,Not Applicable

Isophosphamide mustard

Phase 3,Phase 2

Angiogenesis Inhibitors

Phase 3,Phase 2,Phase 1

Angiogenesis Modulating Agents

Phase 3,Phase 2,Phase 1

Antineoplastic Agents, Immunological

Phase 3,Phase 2,Phase 1

Antibiotics, Antitubercular

Phase 3,Phase 2,Phase 1

Topoisomerase Inhibitors

Phase 3,Phase 2,Phase 1

Anti-Bacterial Agents

Phase 3,Phase 2,Phase 1

Poly(ADP-ribose) Polymerase Inhibitors

Phase 2, Phase 3,Phase 1

Anti-Allergic Agents

Phase 3

Histamine Phosphate

Phase 3

51-74-1

65513

Neurotransmitter Agents

Phase 3

Histamine H1 Antagonists

Phase 3

Serotonin Agents

Phase 3

Serotonin Antagonists

Phase 3

Gastrointestinal Agents

Phase 3

Histamine Antagonists

Phase 3

Antipruritics

Phase 3

Dermatologic Agents

Phase 3

Serotonin

Investigational, Nutraceutical

Phase 3

50-67-9

5202

Temozolomide

Approved, Investigational

Phase 2

85622-93-1

5394

Oxaliplatin

Approved, Investigational

Phase 2

61825-94-3

6857599 5310940 9887054 43805

Docetaxel

Approved, Investigational

Phase 2,Phase 1

114977-28-5

148124

Sorafenib

Approved, Investigational

Phase 2

284461-73-0

216239 406563

Sunitinib

Approved, Investigational

Phase 2

557795-19-4, 341031-54-7

5329102

Sirolimus

Approved, Investigational

Phase 2

53123-88-9

46835353 6436030 5284616

Miconazole

Approved, Investigational, Vet_approved

Phase 2

22916-47-8

4189

Everolimus

Approved

Phase 2

159351-69-6

6442177 70789204

Trabectedin

Approved, Investigational

Phase 2

114899-77-3

108150

Cetuximab

Approved

Phase 2

205923-56-4

56842117 2333

Durvalumab

Approved, Investigational

Phase 2

1428935-60-7

Interventional clinical trials:

(show top 50) (show all 85)

#	Name	Status	NCT ID	Phase	Drugs
1	Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus	Completed	NCT00003128	Phase 3	ifosfamide;paclitaxel
2	Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus	Completed	NCT00002546	Phase 3	cisplatin;ifosfamide
3	Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the Uterus	Completed	NCT00002459	Phase 3
4	Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer	Completed	NCT00483782	Phase 3	carboplatin;paclitaxel
5	Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma	Completed	NCT00002641	Phase 3	doxorubicin hydrochloride;ifosfamide;isolated perfusion
6	Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer	Recruiting	NCT03422198	Phase 3
7	Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer	Active, not recruiting	NCT00954174	Phase 3	Carboplatin;Ifosfamide;Paclitaxel
8	Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib	Not yet recruiting	NCT03651206	Phase 2, Phase 3	Niraparib;Chemotherapy Drugs
9	Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer	Terminated	NCT01132547	Phase 3	cyproheptadine hydrochloride
10	Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble -	Unknown status	NCT02203760	Phase 2	Pazopanib plus Gemcitabine;Pazopanib
11	Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	Unknown status	NCT00838656	Phase 2	carboplatin;gemcitabine hydrochloride;paclitaxel
12	Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma	Unknown status	NCT00003718	Phase 2	temozolomide
13	Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma	Completed	NCT00687687	Phase 2	paclitaxel;carboplatin;BSI-201 (Iniparib)
14	Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus	Completed	NCT00025506	Phase 2	Thalidomide
15	Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus	Completed	NCT00502203	Phase 2	Carboplatin;Paclitaxel
16	Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus	Completed	NCT00476086	Phase 2	Gemcitabine;Oxaliplatin
17	Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer	Completed	NCT01247571	Phase 2	Pazopanib Hydrochloride
18	Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer	Completed	NCT01168232	Phase 2	Ixabepilone
19	Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer	Completed	NCT00114218	Phase 2	Gemcitabine Hydrochloride;Docetaxel
20	Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer	Completed	NCT00075400	Phase 2	imatinib mesylate
21	Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer	Completed	NCT00238121	Phase 2	sorafenib tosylate
22	Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer	Completed	NCT00112489	Phase 2	carboplatin;paclitaxel
23	Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors	Completed	NCT00815945	Phase 2	PegLiposomal Doxorubicin;Carboplatin
24	Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma	Completed	NCT00390234	Phase 2	ziv-aflibercept
25	Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer	Completed	NCT00416455	Phase 1, Phase 2	ferumoxtran-10
26	Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer	Completed	NCT00511992	Phase 2	Avastin;Paclitaxel;Cisplatin
27	Adjuvant Radiation Therapy With Ifosfamide in Patients With Mixed Mesodermal Tumors of the Uterus	Completed	NCT00231842	Phase 2	Ifosfamide;Cisplatin
28	A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma	Completed	NCT00231868	Phase 2	Carboplatin and Paclitaxel and Pelvic Radiation Therapy;Carboplatin and Paclitaxel and Radiation Therapy
29	Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas	Completed	NCT00474994	Phase 2	sunitinib malate
30	Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer	Completed	NCT01010126	Phase 2	Temsirolimus
31	AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma	Completed	NCT00659360	Phase 2	saracatinib
32	Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma	Completed	NCT00245102	Phase 2	sorafenib tosylate
33	Chemotherapy in Treating Patients With Sarcoma of the Uterus	Completed	NCT00005643	Phase 2	pegylated liposomal doxorubicin hydrochloride
34	Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract	Completed	NCT00003334	Phase 2	paclitaxel;pegylated liposomal doxorubicin hydrochloride
35	BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors	Completed	NCT00526149	Phase 2	BI 2536
36	Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma	Completed	NCT00003939	Phase 2	trabectedin
37	STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma	Completed	NCT00006357	Phase 1, Phase 2	imatinib mesylate
38	Thalidomide in Treating Patients With Gynecologic Sarcomas	Completed	NCT00006005	Phase 2	thalidomide
39	Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer	Completed	NCT00032162	Phase 1, Phase 2	carboplatin;pegylated liposomal doxorubicin hydrochloride
40	Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors	Completed	NCT00520013	Phase 2	bevacizumab;erlotinib;paclitaxel;carboplatin
41	Carboplatin Taxol Avastin in Ovarian Cancer (OVCA)	Completed	NCT00129727	Phase 2	Paclitaxel;Carboplatin;Bevacizumab
42	Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer	Completed	NCT00392769	Phase 2	Cetuximab
43	Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)	Recruiting	NCT03648489	Phase 2	Paclitaxel;TAK228
44	A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer	Recruiting	NCT03015129	Phase 2	Durvalumab;Tremelimumab
45	Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel?	Recruiting	NCT03570437	Phase 2	Paclitaxel;Cediranib;Olaparib
46	European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer	Recruiting	NCT03783949	Phase 2	Ganetespib;Niraparib;Carboplatin;Paclitaxel;Gemcitabine
47	A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers	Recruiting	NCT02923934	Phase 2	Ipilimumab;Nivolumab
48	Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer	Recruiting	NCT02874430	Phase 2	Metformin Hydrochloride;Doxycycline
49	Phase II Study of Intrauterine Device (IUD) Alone or in Combination With Everolimus in Endometrial Cancer	Recruiting	NCT02397083	Phase 2	Everolimus
50	A Study of Nivolumab in Selected Uterine Cancer Patients	Recruiting	NCT03241745	Phase 2	Nivolumab

Search NIH Clinical Center for Carcinosarcoma

Cochrane evidence based reviews: carcinosarcoma

Sources

Genetic Tests for Carcinosarcoma

Sources

Anatomical Context for Carcinosarcoma

MalaCards organs/tissues related to Carcinosarcoma:

⁴²

Uterus, Ovary, Breast, Lung, Liver, Cervix, Prostate

Sources

Publications for Carcinosarcoma

Articles related to Carcinosarcoma:

(show top 50) (show all 1703)

#	Title	Authors	Year
1	Cutaneous Carcinosarcoma: a Clinicopathologic and Immunohistochemical Analysis of 11 Korean Cases. ( 30618513 )	Kwak HB...Yun SK	2019
2	Molecular profiling of the biphasic components of hepatic carcinosarcoma by targeted next-generation sequencing. ( 30629754 )	Zhang X...Ji Y	2019
3	Immunohistochemical analysis of the epithelial to mesenchymal transition in uterine carcinosarcoma. ( 30636710 )	Osakabe M...Sugai T	2019
4	Esophageal carcinosarcoma that disappeared pathologically by palliative radiotherapy alone. ( 30649679 )	Kimura K...Takehara T	2019
5	Carcinosarcoma of the esophagus: A report of 6 cases associated with zinc finger E-box-binding homeobox 1 expression. ( 30655804 )	Harada H...Yamashita K	2019
6	The Effect of Fucoidan, a Potential New, Natural, Anti-Neoplastic Agent on Uterine Sarcomas and Carcinosarcoma Cell Lines: ENITEC Collaborative Study. ( 30659312 )	Bobi?ski M...Kotarski J	2019
7	Uterine Inversion as a Result of a Large Prolapsed Carcinosarcoma of the Uterus. ( 30686610 )	Kean SL...Altman AD	2019
8	Carcinosarcoma of Vater's papilla: case report of a rare neoplasm and review of the literature. ( 30706323 )	Itoyama R...Baba H	2019
9	Cytological features of uterine carcinosarcoma: A retrospective study of 20 cases with an emphasis on the usefulness of endometrial cytology. ( 30706679 )	Okano K...Tsuta K	2019
10	A rare case of metastatic skin tumors originating from the sarcomatous component of lung carcinosarcoma. ( 30719994 )	Takashima Y...Shimizu S	2019
11	Multifocal Synchronous Upper Urinary Tract Carcinosarcoma (Sarcomatoid Carcinoma) With Rhabdomyoblastic Differentiation. ( 30767589 )	Takemura K...Koga F	2019
12	Ovarian carcinosarcoma: Current developments and future perspectives. ( 30771873 )	Boussios S...Tatsi K	2019
13	Cutaneous Carcinosarcoma of the Medial Canthus Discovered on Mohs Debulk Analysis. ( 30789518 )	West L...Srivastava D	2019
14	The controversy of esophageal carcinosarcoma: A case report and brief review of literature. ( 30855491 )	Xu X...Dai D	2019
15	Pulmonary carcinosarcoma characterized by small round cells with neuroendocrine, myogenic, and chondrogenic differentiation: An extremely rare case. ( 30864171 )	Nakamura H...Nakatsuka SI	2019
16	Clinical outcomes and patterns of care in the treatment of carcinosarcoma of the breast. ( 30864198 )	Kennedy WR...Zoberi I	2019
17	Effect of Adjuvant Therapy on Oncologic Outcomes of Surgically Approved Stage I Uterine Carcinosarcoma: Turkish Gynecologic Oncology Study ( 30873825 )	Kimyon C?mert G...Y?ce K	2019
18	Carcinosarcoma of the Gallbladder with Chondrosarcomatous Differentiation and Intracytoplasmic Eosinophilic Hyaline Globules (Thanatosomes): A Report of a Case and Review of the Literature. ( 30881717 )	Alratroot JA...Amr SS	2019
19	Primary peritoneal carcinosarcoma: A report of two cases. ( 30910155 )	Fu HS...Chiu YH	2019
20	A successfully treated primary peritoneal carcinosarcoma and serous carcinoma of stage IIIC rescued from hypovolemic shock due to tumor rupture. ( 30910157 )	Huang CC...Kok VC	2019
21	Ovarian Carcinosarcoma and Concurrent Serous Tubal Intraepithelial Carcinoma With Next-Generation Sequencing Suggesting an Origin From the Fallopian Tube. ( 30913944 )	See SHC...Blanco LZ	2019
22	Gas Gangrene of Malignant Mixed Mullerian Tumor of Ovary Caused by Clostridium perfringens. ( 29685470 )	Musikatavorn K....Tarapan T.	2018
23	Lymphadenectomy and Adjuvant Therapy Improve Survival with Uterine Carcinosarcoma: A Large Retrospective Cohort Study. ( 29791913 )	Versluis M.A.C....Nijman H.W.	2018
24	Significance of Lymphovascular Space Invasion by the Sarcomatous Component in Uterine Carcinosarcoma. ( 29971677 )	Matsuo K....Roman L.D.	2018
25	Fluorodeoxyglucose Positron Emission Tomography-computed Tomography Evaluation of an Interesting Case of Uterine Carcinosarcoma with Isolated Appendicular Skeletal Metastases. ( 29643680 )	Harisankar C.N.B.	2018
26	Trends of uterine carcinosarcoma in the United States. ( 29400015 )	Matsuo K....Roman L.D.	2018
27	Tumor Mutational Burden Guides Therapy in a Treatment Refractory<i>POLE-</i>Mutant Uterine Carcinosarcoma. ( 29386312 )	Bhangoo M.S....Klempner S.J.	2018
28	The Association of an Elevated Thrombocyte Count with Clinicopathological Prognostic Factors and Survival in Patients with Uterine Carcinosarcoma. ( 29629727 )	Menczer J....Levy T.	2018
29	Esophageal carcinosarcoma comprised of minimally invasive squamous cell carcinoma and undifferentiated pleomorphic sarcoma: A collision cancer? ( 29934989 )	Miyauchi J....Matsui J.	2018
30	Diagnostic accuracy of 3.0T diffusion-weighted MRI for patients with uterine carcinosarcoma: Assessment of tumor extent and lymphatic metastasis. ( 29437265 )	Huang Y.T....Lai C.H.	2018
31	Insulin-like growth factor 2: a poor prognostic biomarker linked to racial disparity in women with uterine carcinosarcoma. ( 29455465 )	Van Arsdale A.R....Huang G.S.	2018
32	Prognostic Significance of omental Disease and the Role of Omental Sampling in Patients With Uterine Carcinosarcoma. ( 29303931 )	Ross M.S....Taylor S.E.	2018
33	Synchronous endometrial adenocarcinoma and carcinosarcoma in endometrial polyp. ( 29854405 )	Alnimer Y....Azher Q.	2018
34	Carcinosarcoma ex Pleomorphic Adenoma of the Submandibular Gland in a 64-Year-Old Man: A Case Report. ( 29540647 )	Endo Y....Naito Z.	2018
35	Significance of venous thromboembolism in women with uterine carcinosarcoma. ( 29248197 )	Matsuo K....Roman L.D.	2018
36	Usefulness of ascites cytology for the evaluation of chemotherapy response in ovarian carcinosarcoma. ( 29488261 )	Kamii M....Isonishi S.	2018
37	Comparison of first-line chemotherapy regimens for ovarian carcinosarcoma: a single institution case series and review of the literature. ( 29426293 )	Brackmann M....McLean K.	2018
38	Impact of radiotherapy modalities on outcomes in the adjuvant management of uterine carcinosarcoma: A National Cancer Database analysis. ( 29097136 )	Stokes W.A....Fisher C.M.	2018
39	Carcinosarcoma of Breast Mimicking Breast Abscess. ( 30288006 )	Muslim S...Nasrin N	2018
40	Outcomes of carcinosarcoma in a tertiary care institution in India. ( 29600231 )	Cherian AG...Peedicayil A	2018
41	Morphological features of doxorubicin-resistant Walker 256 carcinosarcoma and response of mast cells. ( 29600974 )	Boroday NV...Chekhun VF	2018
42	Coexistence of BRAF V600E and TERT Promoter Mutations in Low-grade Serous Carcinoma of Ovary Recurring as Carcinosarcoma in a Lymph Node: Report of a Case. ( 29620581 )	Tavallaee M...Karam AK	2018
43	Primary Cutaneous Carcinosarcoma: A cutaneous neoplasm with an exceptional presentation. ( 29666695 )	Ruiz-Villaverde R...Aneiros-Fern?ndez J	2018
44	Locally advanced carcinosarcoma of the pancreas. ( 29706823 )	Still SA...Cavaness KM	2018
45	Nab-paclitaxel plus carboplatin as an effective and safe chemotherapy regimen for pulmonary carcinosarcoma with interstitial lung disease: A case report. ( 29719799 )	Niwa H...Masuda N	2018
46	Carcinosarcoma of the esophagus with rapid morphological change. ( 29755123 )	Yabuuchi Y...Ono H	2018
47	Esophageal Carcinosarcoma that Was Diagnosed as a Granulocyte-colony Stimulating Factor and Interleukin-6-producing Tumor with a Tumor Fever. ( 29780130 )	Shioga T...Niino H	2018
48	A Case of Invasive Sinonasal Carcinosarcoma: The Importance of Early Detection. ( 29850334 )	Yuen J...Khalil H	2018
49	Carcinosarcoma of the parotid gland with abdominal metastasis: a case report and review of literature. ( 29859537 )	Woo CG...Son SM	2018
50	Trichoblastic Carcinosarcoma of the Skin: A Case Report and Literature Review. ( 29933313 )	Okhremchuk I...Morand JJ	2018

Sources

Genes for Carcinosarcoma

Genes related to Carcinosarcoma (0 elite genes):

(show all 15)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	37.31	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications Variants (show sections)	16157366 1672262 15581967 (more) 16405663 8630962 15901136
2	VIM	Vimentin	Protein Coding	36.21	Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	1284388 1696005 18281472 (more) 15132766 1283991 9786352 1612579 11180164 15863125
3	KIT	KIT Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	34.43	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	15894930 14529656 20189232 (more) 16306788 16140564 17049587 17367465
4	PGR	Progesterone Receptor	Protein Coding	34.21	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	16648864 19200930 9313326 (more) 11687977 16580307
5	TP53	Tumor Protein P53	Protein Coding	33.95	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Variants (show sections)
6	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	31.02	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Variants (show sections)
7	MUC1	Mucin 1, Cell Surface Associated	Protein Coding	30.5	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	1612579 9786352 1398523 (more) 15863125
8	KRT7	Keratin 7	Protein Coding	30.36	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	12604887
9	PTEN	Phosphatase And Tensin Homolog	Protein Coding	30.19	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Variants (show sections)
10	ACTC1	Actin Alpha Cardiac Muscle 1	Protein Coding	29.84	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	18281472 9500227
11	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	29.76	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Variants (show sections)
12	MME	Membrane Metalloendopeptidase	Protein Coding	28.89	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	12218209
13	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	28.36	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	20203229
14	CTNNB1	Catenin Beta 1	Protein Coding	26.41	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	15223963
15	DES	Desmin	Protein Coding	26.23	Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	1398523 1283991 1612579 (more) 16792552

Sources

Variations for Carcinosarcoma

Cosmic variations for Carcinosarcoma:

⁹ (show top 50) (show all 124)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location
1	COSM1235014	U2AF1	cervix,NS,carcinoma,adenocarcinoma	c.467G>A	p.R156H	21:43094670-43094670
2	COSM10663	TP53	ovary,NS,carcinoma,adenocarcinoma	c.916C>T	p.R306*	17:7673704-7673704
3	COSM10648	TP53	cervix,NS,carcinoma,adenocarcinoma	c.524G>A	p.R175H	17:7675088-7675088
4	COSM44399	TP53	cervix,NS,carcinoma,adenocarcinoma	c.677G>T	p.G226V	17:7674286-7674286
5	COSM11066	TP53	ovary,NS,carcinoma,adenocarcinoma	c.578A>T	p.H193L	17:7674953-7674953
6	COSM10738	TP53	ovary,NS,carcinoma,adenocarcinoma	c.542G>A	p.R181H	17:7675070-7675070
7	COSM11148	TP53	ovary,NS,carcinoma,adenocarcinoma	c.476C>T	p.A159V	17:7675136-7675136
8	COSM10941	TP53	cervix,NS,carcinoma,adenocarcinoma	c.730G>A	p.G244S	17:7674233-7674233
9	COSM10725	TP53	cervix,NS,carcinoma,adenocarcinoma	c.701A>G	p.Y234C	17:7674262-7674262
10	COSM10662	TP53	cervix,NS,carcinoma,adenocarcinoma	c.743G>A	p.R248Q	17:7674220-7674220
11	COSM11333	TP53	cervix,NS,carcinoma,adenocarcinoma	c.499C>T	p.Q167*	17:7675113-7675113
12	COSM11582	TP53	ovary,NS,carcinoma,adenocarcinoma	c.395A>G	p.K132R	17:7675217-7675217
13	COSM10656	TP53	cervix,NS,carcinoma,adenocarcinoma	c.742C>T	p.R248W	17:7674221-7674221
14	COSM6904336	TNFAIP3	ovary,NS,carcinoma,adenocarcinoma	c.940G>A	p.V314I	6:137877210-137877210
15	COSM29468	STK11	cervix,NS,carcinoma,adenocarcinoma	c.910C>T	p.R304W	19:1221996-1221996
16	COSM29467	STK11	cervix,NS,carcinoma,adenocarcinoma	c.894C>A	p.F298L	19:1221980-1221980
17	COSM14135	SMAD4	ovary,NS,carcinoma,adenocarcinoma	c.1051G>C	p.D351H	18:51065518-51065518
18	COSM6904335	SMAD2	ovary,NS,carcinoma,adenocarcinoma	c.785-1G>C	p.?	18:47848688-47848688
19	COSM6967953	SF3B1	cervix,NS,carcinoma,adenocarcinoma	c.1910C>G	p.S637C	2:197402723-197402723
20	COSM6967952	SF3B1	cervix,NS,carcinoma,adenocarcinoma	c.2323C>G	p.R775G	2:197401789-197401789
21	COSM6923797	RET	cervix,NS,carcinoma,adenocarcinoma	c.1132G>A	p.D378N	10:43109099-43109099
22	COSM6904334	RET	ovary,NS,carcinoma,adenocarcinoma	c.3253A>G	p.T1085A	10:43128177-43128177
23	COSM5802682	PTPRD	cervix,NS,carcinoma,adenocarcinoma	c.3530G>A	p.R1177H	9:8465650-8465650
24	COSM5154	PTEN	cervix,NS,carcinoma,adenocarcinoma	c.697C>T	p.R233*	10:87957915-87957915
25	COSM5219	PTEN	cervix,NS,carcinoma,adenocarcinoma	c.388C>G	p.R130G	10:87933147-87933147
26	COSM5056	PTEN	cervix,NS,carcinoma,adenocarcinoma	c.1093G>A	p.V365I	10:87965353-87965353
27	COSM5152	PTEN	cervix,NS,carcinoma,adenocarcinoma	c.388C>T	p.R130*	10:87933147-87933147
28	COSM88109	PTEN	cervix,NS,carcinoma,adenocarcinoma	c.724G>T	p.E242*	10:87957942-87957942
29	COSM6904339	PTCH1	ovary,NS,carcinoma,adenocarcinoma	c.3074G>A	p.R1025H	9:95458107-95458107
30	COSM27133	PIK3CA	cervix,NS,carcinoma,adenocarcinoma	c.1633G>C	p.E545Q	3:179218303-179218303
31	COSM6147	PIK3CA	cervix,NS,carcinoma,adenocarcinoma	c.1636C>G	p.Q546E	3:179218306-179218306
32	COSM760	PIK3CA	ovary,NS,carcinoma,adenocarcinoma	c.1624G>A	p.E542K	3:179218294-179218294
33	COSM770	PIK3CA	ovary,NS,carcinoma,adenocarcinoma	c.2725T>C	p.F909L	3:179230062-179230062
34	COSM763	PIK3CA	cervix,NS,carcinoma,adenocarcinoma	c.1633G>A	p.E545K	3:179218303-179218303
35	COSM21446	PIK3CA	ovary,NS,carcinoma,adenocarcinoma	c.3012G>T	p.M1004I	3:179234169-179234169
36	COSM29313	PIK3CA	cervix,NS,carcinoma,adenocarcinoma	c.3129G>A	p.M1043I	3:179234286-179234286
37	COSM746	PIK3CA	ovary,NS,carcinoma,adenocarcinoma	c.263G>A	p.R88Q	3:179199088-179199088
38	COSM24712	PIK3CA	cervix,NS,carcinoma,adenocarcinoma	c.1638G>T	p.Q546H	3:179218308-179218308
39	COSM775	PIK3CA	cervix,NS,carcinoma,adenocarcinoma	c.3140A>G	p.H1047R	3:179234297-179234297
40	COSM759	PIK3CA	cervix,NS,carcinoma,adenocarcinoma	c.1616C>G	p.P539R	3:179218286-179218286
41	COSM94978	PIK3CA	ovary,NS,carcinoma,adenocarcinoma	c.1034A>T	p.N345I	3:179203764-179203764
42	COSM12584	PIK3CA	cervix,NS,carcinoma,adenocarcinoma	c.1357G>A	p.E453K	3:179210291-179210291
43	COSM766	PIK3CA	ovary,NS,carcinoma,adenocarcinoma	c.1636C>A	p.Q546K	3:179218306-179218306
44	COSM564	NRAS	ovary,NS,carcinoma,adenocarcinoma	c.35G>A	p.G12D	1:114716126-114716126
45	COSM584	NRAS	cervix,NS,carcinoma,adenocarcinoma	c.182A>G	p.Q61R	1:114713908-114713908
46	COSM580	NRAS	ovary,NS,carcinoma,adenocarcinoma	c.181C>A	p.Q61K	1:114713909-114713909
47	COSM522	KRAS	ovary,NS,carcinoma,adenocarcinoma	c.35G>C	p.G12A	12:25245350-25245350
48	COSM517	KRAS	cervix,NS,carcinoma,adenocarcinoma	c.34G>A	p.G12S	12:25245351-25245351
49	COSM516	KRAS	cervix,NS,carcinoma,adenocarcinoma	c.34G>T	p.G12C	12:25245351-25245351
50	COSM521	KRAS	cervix,NS,carcinoma,adenocarcinoma	c.35G>A	p.G12D	12:25245350-25245350

Sources

Expression for Carcinosarcoma

Search GEO for disease gene expression data for Carcinosarcoma.

Sources

Pathways for Carcinosarcoma

Pathways related to Carcinosarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 86)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁷ Show member pathways Immune System ⁶⁷ Neutrophil degranulation ⁶⁷	14.01	CTNNB1 ERBB2 HRAS KIT KRAS MME
2	ERK Signaling ⁶⁵ Show member pathways ILK Signaling ⁶⁵ MAPK Signaling ⁶⁵ Molecular Mechanisms of Cancer ⁶⁵ Rho Family GTPases ⁶⁵	13.84	CTNNB1 DES ERBB2 HRAS KIT KRAS
3	Developmental Biology ⁶⁷ Show member pathways Axon guidance ⁶⁷	13.5	CTNNB1 ERBB2 HRAS KIT KRAS KRT7
4	Class I MHC mediated antigen processing and presentation ⁶⁷ Show member pathways Adaptive Immune System ⁶⁷ Antigen processing- Ubiquitination and Proteasome degradation ⁶⁷	13.45	ERBB2 HRAS KIT KRAS PIK3CA PTEN
5	Cytokine Signaling in Immune system ⁶⁷ Show member pathways Signaling by Interleukins ⁶⁷	13.36	ERBB2 HRAS KIT KRAS MUC1 PIK3CA
6	PAK Pathway ⁶⁵ Show member pathways Antioxidant Action of Vitamin-C ⁶⁵ Epithelial Adherens Junctions ⁶⁵	13.3	CTNNB1 ERBB2 HRAS KIT KRAS PTEN
7	Nanog in Mammalian ESC Pluripotency ⁶⁵ Show member pathways 14-3-3 Induced Intracellular Signaling ⁶⁵ eNOS Signaling ⁶⁵ GSK3 Signaling ⁶⁵	13.28	CTNNB1 ERBB2 HRAS KIT KRAS VIM
8	Human cytomegalovirus infection ³⁸ Show member pathways Human immunodeficiency virus 1 infection ³⁸ Kaposi sarcoma-associated herpesvirus infection ³⁸	12.97	CTNNB1 HRAS KRAS PIK3CA PTEN TP53
9	TNFR1 Pathway ⁶⁵ Show member pathways Apoptosis and survival TNFR1 signaling pathway ²³ Apoptosis through Death Receptors ⁶⁵ Apoptotic Pathways Triggered By HIV1 ⁶⁵ DR3 Signaling ⁶⁵ Fas Signaling ⁶⁵ GITR Pathway ⁶⁵ HIV-1 Nef- Negative effector of Fas and TNF-alpha ¹ Stimulation of the cell death response by PAK-2p34 ⁶⁷ TNF alpha Signaling Pathway ¹ TNF related weak inducer of apoptosis (TWEAK) Signaling Pathway ¹ TNF Signaling ⁶⁵ TRAIL Pathway ⁶⁵ TWEAK Pathway ⁶⁵	12.96	CTNNB1 HRAS KRAS PIK3CA PTEN TP53
10	Regulation of lipid metabolism Insulin signaling-generic cascades ²³ Show member pathways acetyl-CoA biosynthesis from citrate ¹ Butyrate-induced histone acetylation ¹ Cell adhesion PLAU signaling ²³ Class IB PI3K non-lipid kinase events ¹ Development CNTF receptor signaling ²³ Development Growth hormone signaling via PI3K/AKT and MAPK cascades ²³ ErbB2/ErbB3 signaling events ¹ Glucose Homeostasis ¹ Insulin signaling pathway ³⁸ IRS activation ⁶⁷ Signal attenuation ⁶⁷ Transcription Receptor-mediated HIF regulation ²³ Translation Regulation of EIF2 activity ²³ Translation Regulation of EIF4F activity ²³ Translation Insulin regulation of translation ²³	12.91	ERBB2 HRAS KRAS PIK3CA PTEN
11	Focal Adhesion ¹ ³⁸ Show member pathways HGF Pathway ⁶⁵ Integrin-mediated Cell Adhesion ¹	12.91	CTNNB1 ERBB2 HRAS KRAS PIK3CA PTEN
12	PI3K-Akt signaling pathway ³⁸ Show member pathways Human papillomavirus infection ³⁸	12.91	CTNNB1 ERBB2 HRAS KIT KRAS PIK3CA
13	NFAT and Cardiac Hypertrophy ⁶⁵ Show member pathways IGF1R Signaling ⁶⁵ Signaling Involved in Cardiac Hypertrophy ⁶⁵	12.88	ERBB2 HRAS KRAS PIK3CA PTEN
14	MAPK signaling pathway ¹ ³⁸	12.78	ERBB2 HRAS KIT KRAS TP53
15	Ras signaling pathway ³⁸ Show member pathways Rap1 signaling pathway ³⁸	12.75	CTNNB1 HRAS KIT KRAS PIK3CA
16	Endometrial cancer ³⁸ Show member pathways Acute myeloid leukemia ³⁸ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁷ Chronic myeloid leukemia ³⁸ Colorectal cancer ³⁸ Pancreatic cancer ³⁸ Prostate cancer ³⁸ Signal transduction PTEN pathway ²³ Thyroid cancer ³⁸	12.72	CTNNB1 ERBB2 HRAS KIT KRAS PIK3CA
17	Glioma ³⁸ Show member pathways Endocrine resistance ³⁸ Melanoma ³⁸ Non-small cell lung cancer ³⁸ Signaling Pathways in Glioblastoma ¹	12.71	ERBB2 HRAS KRAS PIK3CA PTEN TP53
18	Development Endothelin-1/EDNRA signaling ²³ Show member pathways Cytoskeleton remodeling FAK signaling ²³ Development Endothelin-1/EDNRA transactivation of EGFR ²³ GnRH signaling pathway ³⁸ Inflammatory mediator regulation of TRP channels ³⁸	12.69	CTNNB1 HRAS KRAS PIK3CA PTEN
19	Downstream signaling events of B Cell Receptor (BCR) ⁶⁷ Show member pathways Activation of RAS in B cells ⁶⁷ Signaling by the B Cell Receptor (BCR) ⁶⁷	12.69	ERBB2 HRAS KIT KRAS PIK3CA PTEN
20	Development HGF signaling pathway ²³ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²³ Apoptosis and survival NGF signaling pathway ²³ Apoptosis and survival Role of CDK5 in neuronal death and survival ²³ Development Neurotrophin family signaling ²³ MET activates PTPN11 ⁶⁷ MET activates STAT3 ⁶⁷ Neurotrophin signaling pathway ³⁸ Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) ¹ Signaling of Hepatocyte Growth Factor Receptor ¹	12.67	CTNNB1 ERBB2 HRAS KRAS PIK3CA PTEN
21	Pathways in cancer ³⁸	12.65	CTNNB1 ERBB2 HRAS KIT KRAS PIK3CA
22	Immune response IL-23 signaling pathway ²³ Show member pathways Angiopoietin receptor Tie2-mediated signaling ¹ Angiopoietin-TIE2 Signaling ⁶⁵ Development Angiopoietin - Tie2 signaling ²³ Development PDGF signaling via STATs and NF-kB ²³ IL23-mediated signaling events ¹ Immune response IL-10 signaling pathway ²³ Rac1/Pak1/p38/MMP-2 pathway ¹	12.63	CTNNB1 ERBB2 HRAS KRAS PIK3CA TP53
23	ErbB signaling pathway ¹ ³⁸ Show member pathways EGFR Inhibitor Pathway, Pharmacodynamics ⁶² EGFR tyrosine kinase inhibitor resistance ³⁸ Renal cell carcinoma ³⁸ TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer ¹	12.61	ERBB2 HRAS KRAS PIK3CA TP53
24	Immune response Fc epsilon RI pathway ²³ Show member pathways Fc epsilon RI signaling pathway ³⁸ Fc-epsilon receptor I signaling in mast cells ¹ Immune response BCR pathway ²³ VEGF signaling pathway ³⁸	12.59	HRAS KRAS PIK3CA PTEN
25	Cytoskeletal Signaling ⁴	12.55	ACTC1 DES KRT7 MUC1 VIM
26	mTOR signaling pathway (KEGG) ⁶⁶ Show member pathways mTOR signaling pathway ³⁸	12.54	ERBB2 HRAS KRAS PIK3CA PTEN TP53
27	Prolactin Signaling Pathway ¹ ³⁸ Show member pathways Development Prolactin receptor signaling ²³ Leptin signaling pathway ¹	12.51	ERBB2 HRAS KRAS PIK3CA PTEN
28	Gastric cancer ³⁸ Show member pathways Breast cancer ³⁸ Hepatocellular carcinoma ³⁸	12.48	CTNNB1 ERBB2 HRAS KIT KRAS PGR
29	Apoptosis Pathway ⁷³ Show member pathways Akt Pathway ⁷³ NF-kappaB Pathway ⁷³	12.47	CTNNB1 ERBB2 HRAS KRAS PIK3CA TP53
30	T cell receptor signaling pathway ³⁸ Show member pathways T-Cell antigen Receptor (TCR) Signaling Pathway ¹ T-Cell antigen Receptor (TCR) pathway during Staphylococcus aureus infection ¹	12.45	HRAS KRAS PIK3CA VIM
31	Arrhythmogenic right ventricular cardiomyopathy (ARVC) ³⁸ Show member pathways Arrhythmogenic Right Ventricular Cardiomyopathy ¹ Calpain Protease Regulates Cellular Mechanics ⁶⁵	12.44	CTNNB1 DES HRAS KRAS
32	Phospholipase D signaling pathway ³⁸ Show member pathways Choline metabolism in cancer ³⁸	12.43	HRAS KIT KRAS PIK3CA
33	Development VEGF signaling via VEGFR2 - generic cascades ²³ Show member pathways Development VEGF signaling and activation ²³ VEGF - VEGF R2 Signaling Pathways ⁶⁶	12.42	CTNNB1 HRAS KRAS PIK3CA
34	G-protein signaling RAC1 in cellular process ²³ Show member pathways CDC42 signaling events ¹ Cytoskeleton remodeling CDC42 in cellular processes ²³ RAC1 signaling pathway ¹	12.42	CTNNB1 ERBB2 HRAS KIT KRAS PIK3CA
35	Development IGF-1 receptor signaling ²³ Show member pathways IL-4 Signaling Pathway ¹ Immune response IL-4 signaling pathway ²³ Signal transduction AKT signaling ²³	12.41	HRAS PIK3CA PTEN TP53
36	B cell receptor signaling pathway (KEGG) ³⁸ Show member pathways B Cell Receptor Signaling Pathway ¹ BCR signaling pathway ¹	12.4	HRAS KRAS PIK3CA PTEN
37	Human T-cell leukemia virus 1 infection ³⁸	12.39	CTNNB1 HRAS KRAS PIK3CA TP53
38	B Cell Receptor Signaling Pathway (sino) ⁶⁸ Show member pathways B Cell Receptor Signaling Pathway ⁶⁸	12.35	HRAS KRAS PIK3CA PTEN
39	Signaling by ERBB2 ⁶⁷ Show member pathways Downregulation of ERBB2 signaling ⁶⁷ Downregulation of ERBB2-ERBB3 signaling ⁶⁷ ERBB2 Activates PTK6 Signaling ⁶⁷ ERBB2 Regulates Cell Motility ⁶⁷ GRB2 events in ERBB2 signaling ⁶⁷ PI3K events in ERBB2 signaling ⁶⁷ PI3K events in ERBB4 signaling ⁶⁷ SHC1 events in ERBB2 signaling ⁶⁷ SHC1 events in ERBB4 signaling ⁶⁷	12.32	ERBB2 HRAS KRAS PIK3CA
40	Viral carcinogenesis ³⁸	12.32	HRAS KRAS PIK3CA TP53
41	MicroRNAs in cancer ³⁸	12.28	ERBB2 HRAS KRAS PIK3CA PTEN TP53
42	MAPK Signaling: Mitogen Stimulation Pathway ⁶⁶ Show member pathways Akt Signaling Pathway ⁶⁶	12.24	ERBB2 HRAS KRAS PIK3CA PTEN TP53
43	Proteoglycans in cancer ³⁸	12.24	CTNNB1 ERBB2 HRAS KRAS PIK3CA TP53
44	Cellular senescence (KEGG) ³⁸	12.22	HRAS KRAS PIK3CA PTEN TP53
45	EGF/EGFR Signaling Pathway ¹	12.21	ERBB2 HRAS KRAS PTEN
46	Kit receptor signaling pathway ¹ Show member pathways IL-3 Signaling Pathway ¹ Signaling events mediated by Stem cell factor receptor (c-Kit) ¹	12.2	HRAS KIT PIK3CA PTEN
47	mTOR Pathway ⁷³ Show member pathways Insulin Pathway ⁷³ TGF-beta Pathway ⁷³	12.2	HRAS KRAS PIK3CA TP53
48	Development EGFR signaling via small GTPases ²³ Show member pathways Development EGFR signaling via PIP3 ²³ Development PDGF signaling via MAPK cascades ²³ PDGF Pathway ¹	12.19	ERBB2 HRAS KRAS PIK3CA PTEN
49	Integrated Breast Cancer Pathway ¹	12.18	CTNNB1 KRAS PTEN TP53
50	Longevity regulating pathway ³⁸ Show member pathways Longevity regulating pathway - multiple species ³⁸	12.17	HRAS KRAS PIK3CA TP53

Sources

GO Terms for Carcinosarcoma

Cellular components related to Carcinosarcoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	cytosol	GO:0005829	9.73	ACTC1 CTNNB1 DES ERBB2 HRAS KRAS
2	focal adhesion	GO:0005925	9.55	ACTC1 CTNNB1 KRAS MME VIM
3	cytoplasm	GO:0005737	9.5	ACTC1 CTNNB1 DES ERBB2 HRAS KIT
4	fascia adherens	GO:0005916	9.32	CTNNB1 DES
5	plasma membrane	GO:0005886	10	CTNNB1 DES ERBB2 HRAS KIT KRAS

Biological processes related to Carcinosarcoma according to GeneCards Suite gene sharing:

(show all 20)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of cell proliferation	GO:0008284	9.92	CTNNB1 HRAS KIT KRAS PTEN
2	cell proliferation	GO:0008283	9.8	CTNNB1 ERBB2 HRAS PTEN TP53
3	phosphatidylinositol phosphorylation	GO:0046854	9.76	ERBB2 KIT PIK3CA
4	MAPK cascade	GO:0000165	9.76	ERBB2 HRAS KIT KRAS
5	positive regulation of DNA-binding transcription factor activity	GO:0051091	9.75	CTNNB1 KIT PTEN
6	positive regulation of ERK1 and ERK2 cascade	GO:0070374	9.69	HRAS KIT PTEN
7	Ras protein signal transduction	GO:0007265	9.67	HRAS KRAS TP53
8	positive regulation of MAPK cascade	GO:0043410	9.62	CTNNB1 ERBB2 HRAS KIT
9	stimulatory C-type lectin receptor signaling pathway	GO:0002223	9.61	HRAS KRAS MUC1
10	epithelial tube branching involved in lung morphogenesis	GO:0060441	9.59	CTNNB1 KRAS
11	regulation of synaptic transmission, GABAergic	GO:0032228	9.57	KRAS PTEN
12	DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	GO:0006978	9.56	MUC1 TP53
13	negative regulation of apoptotic process	GO:0043066	9.56	ACTC1 CTNNB1 PTEN TP53
14	positive regulation of phospholipase C activity	GO:0010863	9.55	HRAS KIT
15	replicative senescence	GO:0090399	9.54	MME TP53
16	muscle filament sliding	GO:0030049	9.54	ACTC1 DES VIM
17	response to isolation stress	GO:0035900	9.48	HRAS KRAS
18	positive regulation of MAP kinase activity	GO:0043406	9.46	ERBB2 HRAS KIT KRAS
19	cytokine-mediated signaling pathway	GO:0019221	9.43	KIT KRAS MUC1 PIK3CA TP53 VIM
20	positive regulation of gene expression	GO:0010628	9.28	ACTC1 CTNNB1 ERBB2 HRAS KIT KRAS

Molecular functions related to Carcinosarcoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	identical protein binding	GO:0042802	9.8	DES ERBB2 PGR PTEN TP53 VIM
2	protein phosphatase binding	GO:0019903	9.43	CTNNB1 ERBB2 TP53
3	phosphatidylinositol-4,5-bisphosphate 3-kinase activity	GO:0046934	9.13	ERBB2 KIT PIK3CA
4	protein C-terminus binding	GO:0008022	8.92	CTNNB1 ERBB2 HRAS VIM
5	protein binding	GO:0005515	10	CTNNB1 DES ERBB2 HRAS KIT KRAS

Sources

Sources for Carcinosarcoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FDA Approved Drugs

²⁰ FMA

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ Genetics Home Reference

²⁷ GenomeRNAi

²⁸ GEO DataSets

²⁹ GO

³⁰ GTR

³¹ HGMD

³² HMDB

³³ HPO

³⁴ ICD10

³⁵ ICD10 via Orphanet

³⁶ ICD9CM

³⁷ IUPHAR

³⁸ KEGG

³⁹ LifeMap

⁴⁰ LncRNADisease

⁴¹ LOVD

⁴² MalaCards

⁴³ MedGen

⁴⁴ MedlinePlus

⁴⁵ MeSH

⁴⁶ MESH via Orphanet

⁴⁷ MGI

⁴⁸ miR2Disease

⁴⁹ NCBI Bookshelf

⁵⁰ NCI

⁵¹ NCIt

⁵² NDF-RT

⁵³ NIH Clinical Center

⁵⁴ NIH Rare Diseases

⁵⁵ NINDS

⁵⁶ Novoseek

⁵⁷ Novus Biologicals

⁵⁸ OMIM

⁵⁹ OMIM via Orphanet

⁶⁰ Orphanet

⁶¹ PathCards

⁶² PharmGKB

⁶³ PubMed

⁶⁴ PubMed Health

⁶⁵ QIAGEN

⁶⁶ R&D Systems

⁶⁷ Reactome

⁶⁸ Sino Biological

⁶⁹ SNOMED-CT

⁷⁰ SNOMED-CT via HPO

⁷¹ SNOMED-CT via Orphanet

⁷² TGDB

⁷³ Tocris

⁷⁴ UMLS

⁷⁵ UMLS via Orphanet

⁷⁶ UniProtKB/Swiss-Prot

⁷⁷ Wikipedia

Carcinosarcoma (MMMT)

Aliases & Classifications for Carcinosarcoma

MalaCards integrated aliases for Carcinosarcoma:

Classifications:

External Ids:

Summaries for Carcinosarcoma

Related Diseases for Carcinosarcoma

Diseases related to Carcinosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Carcinosarcoma:

Symptoms & Phenotypes for Carcinosarcoma

GenomeRNAi Phenotypes related to Carcinosarcoma according to GeneCards Suite gene sharing:

MGI Mouse Phenotypes related to Carcinosarcoma:

Drugs & Therapeutics for Carcinosarcoma

Drugs for Carcinosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Cochrane evidence based reviews: carcinosarcoma

Genetic Tests for Carcinosarcoma

Anatomical Context for Carcinosarcoma

MalaCards organs/tissues related to Carcinosarcoma:

Publications for Carcinosarcoma

Articles related to Carcinosarcoma:

Genes for Carcinosarcoma

Genes related to Carcinosarcoma (0 elite genes):

Variations for Carcinosarcoma

Cosmic variations for Carcinosarcoma:

Expression for Carcinosarcoma

Pathways for Carcinosarcoma

Pathways related to Carcinosarcoma according to GeneCards Suite gene sharing:

GO Terms for Carcinosarcoma

Cellular components related to Carcinosarcoma according to GeneCards Suite gene sharing:

Biological processes related to Carcinosarcoma according to GeneCards Suite gene sharing:

Molecular functions related to Carcinosarcoma according to GeneCards Suite gene sharing:

Sources for Carcinosarcoma